A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
← catalyst calendarNCT07412704 · readout in 1,168 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1/2
Status
Not yet recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
84estimated
Sites
43
Countries
Belgium, Brazil, China +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-09-15 | estimated | When the study began enrolling |
| Primary completion | 2029-10-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-09-02 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Arthritis, Rheumatoid
Intervention
- Drug: BMS-986528
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with treatment-emergent adverse events (TEAEs)
measured Up to Week 54
Number of participants with Serious Adverse Events (SAEs)
measured Up to Week 54
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed